Clinical vs direct-to-consumer genetic testing
Two products that share the word "genetic" but answer different questions. Here is what separates a clinical diagnostic test from a consumer screen — gene coverage, variant classification, regulatory scope, and the counselling that turns a result into a decision.
Two different questions
A clinical genetic test is ordered to answer a medical question — "does this person carry a pathogenic variant that changes their care?" It is performed in an accredited laboratory, interpreted against the ACMG/AMP framework, and returned with counselling. A direct-to-consumer (DTC) test is a product bought without a clinician, designed primarily for ancestry and wellness, that may also report a narrow, fixed list of health-risk markers.
The two can both mention BRCA1 and BRCA2, yet a "negative" carries entirely different weight. The most-cited example is the original DTC BRCA report, which tested only three founder variants — BRCA1 c.68_69delAG, BRCA1 c.5266dupC, and BRCA2 c.5946delT — common in people of Ashkenazi Jewish descent and rare elsewhere. A clinical test sequences the whole gene.
This page is an educational explainer, not medical advice. For a personal testing decision, speak with a clinician or genetic counsellor.
Clinical vs DTC across the dimensions that matter
A side-by-side of what each pathway actually delivers. Figures are drawn from regulatory authorisations and the peer-reviewed literature cited below.
| Dimension | Clinical diagnostic | Direct-to-consumer (DTC) |
|---|---|---|
| Gene coverage | Full-gene sequencing; panels of ~20 (NCCN-aligned) to 80+ genes incl. BRCA1, BRCA2, PALB2, ATM, CHEK2, TP53 | Fixed marker set; e.g. original BRCA report = 3 founder variants only |
| Method | Next-gen sequencing + large-rearrangement (CNV) analysis | Genotyping microarray — reads pre-selected positions, not the whole gene |
| Variant classification | ACMG/AMP 5-tier (pathogenic → benign), curated by laboratory scientists | Often raw genotype calls; little to no formal classification |
| A "negative" means | No pathogenic variant found across the tested gene(s) | Only that those specific markers were absent — not gene-wide reassurance |
| FDA / regulatory scope | Laboratory-developed test or IVD; ordered through a clinician | FDA-authorised with special controls; explicitly not diagnostic |
| Confirmation | Result is the clinical result | Manufacturers advise confirmatory clinical testing before any action |
| Counselling | Pre- and post-test genetic counselling standard | Typically none; interpretation left to the consumer |
Table 1. Comparative scope of clinical diagnostic and direct-to-consumer genetic testing for hereditary cancer risk.
Why a DTC "BRCA negative" is not a clinical negative
Illustrative comparison of variant coverage. The original DTC report screened 3 founder variants; clinical full-gene sequencing interrogates the entire coding region, where the great majority of pathogenic variants in the general population lie.
Lifetime breast-cancer risk, by carrier status
Why classification accuracy matters: a pathogenic BRCA result substantially shifts lifetime risk, which is why a false positive or a missed variant has real clinical consequences. Cumulative estimates vary by study and methodology; ranges shown.
NCI baseline, women
≈45–47% by age 70
≈55–65% by age 70
Glossary
Terms that recur whenever clinical and consumer testing are compared.
- Founder variant
- A pathogenic variant common in a defined ancestral group because it descends from a shared ancestor — e.g. the three Ashkenazi
BRCAvariants. Screening for these alone misses variants common in other populations. - Genotyping array
- A chip that reads pre-selected genomic positions only. Cheap and fast, but it cannot detect variants it was not designed to interrogate — the core technical limit of most DTC health reports.
- ACMG/AMP tiers
- The 2015 five-level framework — pathogenic, likely pathogenic, VUS, likely benign, benign — weighing 28 evidence criteria. The shared language of clinical variant reporting.
- VUS
- Variant of uncertain significance — detected but not yet classifiable as harmful or harmless. Managed clinically with caution; rarely surfaced or explained in DTC reports.
Common questions
If my DTC test says I have no BRCA variant, am I in the clear?
Not necessarily. A DTC report that screens only selected variants can be negative while you still carry a pathogenic variant elsewhere in BRCA1 or BRCA2. The original FDA-authorised report covered 3 of more than 1,000 known variants. A clinician can advise whether full-gene clinical testing is warranted given your family history.
Why does a DTC test need clinical confirmation?
One peer-reviewed study found roughly 40% of variants flagged in DTC raw data were false positives on clinical re-testing, with most false calls in cancer-related genes. Genotyping arrays are not engineered for the rare, clinically actionable variants that diagnostic sequencing targets, so manufacturers themselves advise confirmation before any medical action.
Is the DTC test FDA-approved as a diagnostic?
No. The DTC BRCA report was authorised with special controls as a consumer health-risk report — explicitly not a diagnostic test and not a substitute for clinician-ordered testing or screening.
What does counselling add that a report cannot?
A genetic counsellor places a result in the context of personal and family history, explains a VUS, and connects findings to screening or prevention pathways. Clinical testing pairs the result with that interpretation; DTC generally leaves it to the reader.
- [1]FDA, 2018. U.S. Food and Drug Administration. "FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes." Press announcement, 6 March 2018.↗
- [2]Richards S et al., 2015. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and the AMP. Genetics in Medicine.↗
- [3]Tandy-Connor S et al., 2018. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing. Genetics in Medicine, 20:1515–1521.↗
- [4]NCI. BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet. National Cancer Institute.↗
- [5]Kuchenbaecker KB et al. / JCO. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology.↗
Coverage and classification decide what a result means
If you are weighing a consumer screen against clinical testing, the next reads explain full-gene panels and how to interpret a report — and why a clinician or genetic counsellor remains the place to take a personal decision.